BPC-157 Dosing Protocols: What Actually Works (2026 Guide)
What Is the Correct BPC-157 Dose?
Standard BPC-157 dosing is 250-500 mcg once or twice daily for 4-8 weeks. Inject subcutaneously near the injury site for localised repair, or at any site for systemic and gut applications. Oral capsules work for gastrointestinal targets. Reconstitute with bacteriostatic water and verify your concentration before every draw.
The most common BPC-157 dosing error is not choosing the wrong amount. It is running a protocol without knowing the concentration you created during reconstitution, which means every dose you draw is a guess. Get the maths right and everything else becomes straightforward. Get it wrong and you are injecting an unknown quantity of an expensive peptide into an injury that deserves precision, not approximation.
This guide covers the complete dosing picture: what BPC-157 is and how it works, reconstitution and concentration calculations, goal-specific protocols by condition, injection technique, sourcing verification, stack options, common mistakes, and the timing structure that produces results.
This content is for educational purposes only. These compounds are intended for research use. Consult a qualified clinician before beginning any peptide protocol.
What Is BPC-157 and Why Does Dosing Precision Matter?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a region of body protection compound found naturally in human gastric juice. Unlike many peptides, BPC-157 is notably stable at room temperature and in the presence of gastric acids, which is part of why it remains active across both oral and injectable administration routes.
Its primary mechanism involves upregulation of growth hormone receptor expression at the tendon-to-bone junction, promotion of nitric oxide synthesis, and activation of the FAK-paxillin pathway that drives fibroblast migration into injured tissue. Preclinical research published in Journal of Physiology and Pharmacology demonstrated accelerated healing of tendons, ligaments, muscle, gut mucosa, bone, and peripheral nerves across multiple animal models (Sikiric et al., 2018).
Dosing precision matters for two reasons. First, BPC-157 is sold as a lyophilised (freeze-dried) powder, usually in 2 mg, 5 mg, or 10 mg vials. You reconstitute it yourself with bacteriostatic water, and any arithmetic error creates an unknown concentration. Second, research suggests a U-shaped dose-response curve at extremes: too little yields no benefit; there is no strong evidence that exceeding 500 mcg per injection adds benefit beyond what 250-500 mcg achieves for most targets.
Reconstitution and Concentration Calculation
Reconstitution is the single most important skill in any peptide protocol. An error here invalidates every subsequent dose calculation.
Equipment checklist
- BPC-157 lyophilised vial (confirm mg amount on label)
- Bacteriostatic water (BAC water) for injection, 30 ml supply minimum
- 1 ml or 2 ml luer-lock syringe
- 29-31 gauge, 0.5 inch insulin syringe for drawing and injecting
- Alcohol swabs
- Sharps container
Standard reconstitution formula
The formula: (BAC water added in ml) × 1000 ÷ (peptide amount in mcg) = mcg per ml. To find how many units to draw on an insulin syringe: desired dose in mcg ÷ concentration in mcg per ml × 100 = units.
| Vial Size | BAC Water Added | Concentration | Units for 250 mcg | Units for 500 mcg |
|---|---|---|---|---|
| 2 mg (2000 mcg) | 2 ml | 1000 mcg/ml | 25 units | 50 units |
| 5 mg (5000 mcg) | 2 ml | 2500 mcg/ml | 10 units | 20 units |
| 5 mg (5000 mcg) | 5 ml | 1000 mcg/ml | 25 units | 50 units |
| 10 mg (10000 mcg) | 10 ml | 1000 mcg/ml | 25 units | 50 units |
Most researchers default to a 1000 mcg/ml concentration because the unit math is simple: 25 units = 250 mcg, 50 units = 500 mcg. If you add a different volume of BAC water, recalculate before every draw. Store reconstituted vials refrigerated at 2-8 degrees Celsius. Most sources report peptide stability for 30-60 days once reconstituted when stored correctly and kept away from repeated freeze-thaw cycles.
For a step-by-step walkthrough of the full reconstitution process, see How to Reconstitute Peptides.
Standard BPC-157 Dosing Protocol
The protocol structure that appears most frequently across the research literature and experienced user reporting breaks down as follows:
| Parameter | Conservative | Standard | High-End |
|---|---|---|---|
| Daily dose | 250 mcg once daily | 250-500 mcg twice daily | 500 mcg twice daily |
| Injection frequency | Once daily | Once or twice daily | Twice daily (AM and PM) |
| Cycle length | 4 weeks | 6-8 weeks | 8-12 weeks |
| Off period | 4 weeks minimum | 4-6 weeks | 6-8 weeks |
| Total per cycle | 7,000-14,000 mcg | 21,000-56,000 mcg | 56,000-84,000 mcg |
Timing: Most practitioners inject in the morning before food, or split AM and PM doses if running twice daily. For gut healing protocols, some researchers administer oral capsules 20-30 minutes before meals on an empty stomach to maximise mucosal contact time.
Injection site: For localised injuries (tendon, ligament, muscle), inject subcutaneously within 2-3 cm of the injury site. For systemic effects, the abdomen, lateral thigh, or upper arm are all appropriate. Rotate injection sites within each area to avoid tissue irritation.
BPC-157 Dosing by Condition
One protocol does not fit every application. The following condition-specific breakdowns reflect what the current preclinical literature and practitioner consensus support.
Tendon and ligament injuries
BPC-157's most documented application in animal models is tendon-to-bone healing. Research published in Journal of Orthopedic Research showed Achilles tendon-to-bone reattachment was significantly accelerated in rats receiving BPC-157 compared to controls (Krivic et al., 2008). Preclinical models have also shown benefit in rotator cuff, quadriceps, and patellar tendon damage.
- Dose: 250-500 mcg subcutaneously, once or twice daily
- Site: Inject near the injury site, not directly into tendon tissue
- Cycle: 6-8 weeks, with a 4-6 week break before reassessment
- Stack option: TB-500 (thymosin beta-4) at 2-5 mg twice weekly is frequently combined for additive connective tissue repair (see The Wolverine Stack: BPC-157 + TB-500)
Muscle tears and post-surgical recovery
For acute muscle tears or post-surgical contexts, BPC-157 appears to accelerate satellite cell migration and myoblast proliferation in animal studies. A review in Current Medical Chemistry (2023) catalogued organ-protective effects across skeletal muscle, smooth muscle, and cardiac muscle models (Sikiric et al., 2023).
- Dose: 250-500 mcg twice daily
- Site: Near the injury site subcutaneously
- Cycle: Start within 48-72 hours of injury; run 6-8 weeks
- Stack option: Pair with TB-500 for muscle repair (see BPC-157 and TB-500 for Post-Surgery Recovery)
Gut and gastrointestinal repair
BPC-157 is uniquely suited to gut repair because of its stability in gastric acid and its direct mucosal contact when taken orally. Research has shown accelerated healing of ulcers, leaky gut, and inflammatory bowel conditions in animal models. The brain-gut axis effects documented by Sikiric et al. suggest BPC-157 modulates both local mucosal integrity and the enteric-central nervous system interface (Sikiric et al., 2012).
- Dose: 250-500 mcg orally, once or twice daily, OR 250 mcg subcutaneously once daily
- Timing: Oral: take on empty stomach, 20-30 minutes before a meal
- Cycle: 6-8 weeks minimum for chronic gut conditions
- Note: For deep gut healing, oral is generally preferred over injectable for this specific application
For a full comparison of how oral and injectable routes differ in practice, see BPC-157 Oral vs Injectable: Which Route Works Better?
Nerve injury and neurological repair
BPC-157's effects on peripheral and central nervous system repair are among its most compelling areas of preclinical investigation. Research published in Regulatory Peptides demonstrated significant improvements in nerve crush injury and nerve transection models, with BPC-157-treated animals recovering motor function faster than controls (Gjurasin et al., 2010). CNS applications including traumatic brain injury and spinal cord contusion models have also been explored (Sikiric et al., 2022).
- Dose: 250 mcg subcutaneously once daily (conservative entry point for systemic nerve applications)
- Site: Systemic injection site is acceptable; proximity to injury site where feasible
- Cycle: 8-12 weeks given slower neurological repair timelines
Bone healing and fracture repair
Multiple animal models show BPC-157 accelerates osteoblast activity and periosteal bone formation at fracture sites. The compound upregulates VEGF expression at the healing site, promoting the vascular supply necessary for bone remodelling.
- Dose: 250-500 mcg subcutaneously once or twice daily
- Site: Near the fracture site if accessible, otherwise abdominal subcutaneous
- Cycle: Run for the duration of expected healing plus 2-4 additional weeks
Systemic recovery and general anti-inflammatory use
For athletes using BPC-157 as a general recovery accelerant or systemic anti-inflammatory rather than targeting a specific injury, lower doses and standard abdominal injection sites are appropriate.
- Dose: 250 mcg once daily
- Site: Abdominal subcutaneous rotation
- Cycle: 4-6 weeks on, 4-6 weeks off
Oral vs Injectable BPC-157: Route Comparison
| Factor | Subcutaneous Injection | Intramuscular Injection | Oral Capsule or Solution |
|---|---|---|---|
| Best application | Localised injury, systemic use | Deep muscle injuries | Gastrointestinal repair |
| Onset | Rapid (direct absorption) | Rapid (direct absorption) | Slower systemic onset |
| Bioavailability concern | High | High | Lower systemically, high locally in GI tract |
| Injection site flexibility | High | Limited to large muscles | N/A |
| Pain or discomfort | Minimal with correct technique | Moderate | None |
| Dose accuracy | High (measured per draw) | High | Moderate (capsule dosing) |
The key insight on oral BPC-157: it is not inferior overall, it is inferior for systemic and localised non-GI applications. For gut repair, oral delivery provides direct mucosal contact that subcutaneous injection cannot replicate efficiently. Pick the route based on the target tissue, not a blanket preference.
BPC-157 Stack Protocols
BPC-157 is frequently combined with other peptides for enhanced recovery outcomes. The most studied and widely used stacks are detailed below.
BPC-157 + TB-500 (The Wolverine Stack)
TB-500 (thymosin beta-4) and BPC-157 address overlapping but distinct repair pathways. BPC-157 drives fibroblast migration and local tissue repair at the injury site. TB-500 promotes systemic actin regulation and cellular migration more broadly, and has demonstrated systemic effects on inflammation and cardiac repair in animal models. Together, they are the most commonly paired peptide combination in the recovery space.
| Compound | Dose | Frequency | Duration |
|---|---|---|---|
| BPC-157 | 250-500 mcg | Once or twice daily | 6-8 weeks |
| TB-500 | 2-5 mg | Twice weekly | 6-8 weeks |
Full protocol details and timing structure are covered in The Wolverine Stack: BPC-157 and TB-500. For standalone TB-500 dosing, see TB-500 Dosage Guide.
BPC-157 + CJC-1295/Ipamorelin
Adding a growth hormone secretagogue stack like CJC-1295/Ipamorelin can amplify the recovery environment by elevating endogenous GH and IGF-1, both of which support collagen synthesis and tissue remodelling. This is a more advanced combination typically used by athletes managing significant injuries while maintaining training continuity.
- BPC-157: 250-500 mcg subcutaneously once or twice daily
- CJC-1295 (no DAC): 100-200 mcg subcutaneously
- Ipamorelin: 100-200 mcg subcutaneously
- CJC-1295/Ipamorelin timing: 30-60 minutes before sleep on an empty stomach
Full CJC-1295/Ipamorelin dosing is covered in CJC-1295 and Ipamorelin Stack Guide.
BPC-157 + GHK-Cu (Skin and Connective Tissue Stack)
GHK-Cu (copper peptide) pairs well with BPC-157 for skin, connective tissue, and anti-ageing applications. GHK-Cu promotes collagen and elastin synthesis and has been shown to reduce systemic inflammation markers in animal models. Combined with BPC-157's fibroblast activation, this stack is used for post-injury cosmetic recovery and general connective tissue maintenance. See GHK-Cu Complete Guide.
Timing, Cycle Structure, and Scheduling
The structure of a BPC-157 protocol matters as much as the dose itself. Here is a practical scheduling framework:
Standard 8-week cycle
- Week 1-2 (ramp): 250 mcg once daily. Observe for any site reactions, nausea, or unexpected effects.
- Week 3-8 (full protocol): 250-500 mcg once or twice daily based on target and response.
- Post-cycle (weeks 9-12): Off period. Assess injury status, range of motion, and pain levels before deciding on a second cycle.
Post-surgery accelerated protocol
- Pre-surgery (if planned): Some practitioners begin BPC-157 1-2 weeks before a scheduled procedure to prime repair pathways.
- Days 1-3 post-surgery: 250 mcg once daily (conservative; allow surgical site to stabilise).
- Days 4-56 post-surgery: 500 mcg twice daily. Focus site near surgical area where accessible.
- Off period: 4-6 weeks after completing an 8-week post-surgical run.
For detailed post-surgery structuring, see BPC-157 and TB-500 for Post-Surgery Recovery.
BPC-157 Side Effects and Safety Profile
BPC-157 has an unusually clean safety profile in animal studies across multiple decades of research. No lethal dose has been established in rodent models. That said, the absence of human clinical trial data means the side effect profile in humans is based on anecdotal reporting rather than controlled studies. Any researcher using these compounds should consult a qualified clinician and monitor subjectively and with labwork.
Reported side effects (from user reports, not clinical trials)
| Side Effect | Frequency Reported | Notes |
|---|---|---|
| Injection site redness or mild swelling | Uncommon | Usually resolves within 24 hours; improve technique and rotate sites |
| Nausea | Uncommon | More common with oral dosing on an empty stomach; take with a small amount of food if persistent |
| Vivid dreams or sleep disruption | Rare | Reported occasionally; move injection timing to morning if this occurs |
| Fatigue or sedation | Rare | Transient; often resolves within the first week |
| Headache | Rare | Usually first 1-3 days; ensure adequate hydration |
| Flushing or warmth at injection site | Uncommon | Related to localised vasodilation via nitric oxide pathways |
Who should not use BPC-157
- Anyone with active cancer or a history of cancer: BPC-157 promotes angiogenesis and cell proliferation. Theoretical risk of accelerating tumour vascularisation has not been ruled out in human models. This is a hard contraindication in most research contexts.
- Pregnant or breastfeeding individuals: No safety data exists for this population.
- Individuals on anticoagulant therapy: BPC-157's effects on platelet function and vascular biology may interact with anticoagulants. Requires clinical supervision.
- Anyone without access to clinical oversight: Because no human clinical trials exist, self-administration without any medical monitoring carries undefined risk. Consult a qualified clinician before starting.
Common BPC-157 Dosing Mistakes
These are the errors that account for most protocol failures and suboptimal outcomes.
Mistake 1: Wrong reconstitution volume
Adding 1 ml of BAC water to a 5 mg vial creates a 5000 mcg/ml concentration, not 1000 mcg/ml. At that concentration, drawing 25 units delivers 1250 mcg, not 250 mcg. Always calculate: (BAC water ml) x 1000 divided by (vial mcg) = concentration per ml. Write it on the vial with a marker before storing.
Mistake 2: Injecting directly into tendon tissue
Peri-tendon subcutaneous injection means near the tendon, not into it. Injecting directly into tendon tissue risks mechanical damage and local inflammatory response. Stay within 2-3 cm of the structure, subcutaneous layer only, and let the peptide diffuse locally.
Mistake 3: Running indefinite cycles without breaks
There is no long-term human data on continuous BPC-157 use. The research convention is structured cycles with off periods. Running continuously removes your ability to assess whether the protocol is working and eliminates the off-period baseline you need for comparison.
Mistake 4: Expecting results without addressing the underlying insult
BPC-157 accelerates repair. It does not repair damage while you continue to inflict it. Continuing to train through a tendon injury while using BPC-157 will not heal the tendon. Load management and relative rest during the protocol cycle are non-negotiable for meaningful outcomes.
Mistake 5: Buying from unverified sources
Purity, sterility, and accurate labelling vary dramatically between peptide suppliers. A 5 mg vial labelled as BPC-157 that is 40% pure or contaminated with endotoxins delivers neither the intended dose nor a safe injection. Third-party certificate of analysis (CoA) testing from a supplier is the minimum verification standard.
Mistake 6: Skipping the compliance disclaimer review
BPC-157's regulatory and sporting status varies by jurisdiction and governing body. Athletes subject to anti-doping testing should review current WADA status before use. See Is BPC-157 Banned by WADA? for the current regulatory picture. For the broader FDA reclassification context affecting peptide availability in the United States, see FDA Reclassification: What It Means for Peptides.
How to Source and Verify BPC-157
The quality of your source determines the quality of your protocol. There is no shortcut here, and price is not a reliable quality signal in either direction.
Minimum verification standards
- Certificate of Analysis (CoA): The supplier should provide a CoA from a third-party analytical lab for each batch. Look for purity above 98% by HPLC and confirmation of the correct molecular weight (1419.5 Da for BPC-157).
- Endotoxin (LAL) test: Endotoxins in injectable peptides cause fever, inflammation, and in high doses, septic shock. Any supplier providing injected peptides should have LAL test results per batch.
- Sterility testing: Particularly important for pre-mixed solutions; less critical for lyophilised powder (which you reconstitute yourself with sterile BAC water), but good suppliers test anyway.
- Accurate labelling: Mg amount, lot number, and expiry on every vial. No label, no purchase.
For BPC-157 sourcing, I use and recommend Real Peptides based on their batch CoA availability and consistent third-party purity testing.
Evidence Overview: What the Research Actually Shows
It is important to understand the nature of BPC-157 research before evaluating the claims made in this and other guides. As of mid-2026, there are no completed human randomised controlled trials for BPC-157. All mechanistic and efficacy data comes from animal models, predominantly rodent studies. This is a critical limitation that affects how confidently any claim can be stated.
| Application | Evidence Level | Number of Animal Studies | Human RCT Data |
|---|---|---|---|
| Tendon healing | Strong (preclinical) | 10+ | None |
| Muscle repair | Moderate (preclinical) | 5-10 | None |
| Gut / GI repair | Strong (preclinical) | 15+ | None |
| Bone healing | Moderate (preclinical) | 5+ | None |
| Nerve repair | Moderate (preclinical) | 5+ | None |
| CNS / TBI applications | Early (preclinical) | 3-5 | None |
| Anti-ageing / longevity | Very early (preclinical) | 2-3 | None |
The strength of BPC-157's preclinical evidence in tendon healing and gut repair is genuinely impressive by the standards of research peptides. The absence of human trials does not mean the compound does not work; it means the risk profile in humans cannot be fully quantified. This is the research context every user needs to understand going in.
For the broader injury recovery peptide landscape, including how BPC-157 compares to other recovery compounds, see Best Peptides for Injury Recovery in 2026.
BPC-157 Regulatory and Legal Status
The regulatory picture for BPC-157 has shifted significantly in the 2024-2026 period. In the United States, the FDA's reclassification of bulk peptides as new drug ingredients affected the legal status of BPC-157 as a compounded pharmaceutical. As of 2026, BPC-157 is sold legally as a research chemical or research peptide in many jurisdictions, but not as a prescription compounded medication in the United States in the same way it was prior to the FDA action.
For athletes: BPC-157 appears on the WADA prohibited list under the category of peptide hormones and related substances. Athletes in tested sports should treat it as prohibited and should review the current WADA list before use. See Is BPC-157 Banned by WADA? for the full breakdown.
For the updated context on peptide legality post-reclassification, see Peptides Legal Again in 2026?
This content is for educational purposes only. These compounds are intended for research use. Consult a qualified clinician before use. Laws and regulations vary by country and change over time. Verify current status in your jurisdiction before purchasing or using any research peptide.
Frequently Asked Questions
References
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. J Physiol Pharmacol. 2018. PubMed 30540927
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of various organ damage. Curr Med Chem. 2023. PubMed 36397627
- Krivic A, et al. Achilles tendon-to-bone reattachment promoted by pentadecapeptide BPC 157. J Orthop Res. 2008. PubMed 18627034
- Sikiric P, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022. PubMed 35799543
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Pharm Des. 2012. PubMed 22950504
- Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010. PubMed 19917303
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
Share this article
Frequently Asked Questions
What is the standard BPC-157 dose for tendon injuries?
How do I calculate how many units to draw for a 250 mcg dose?
How long does a BPC-157 cycle last and when should I take a break?
Is oral BPC-157 as effective as injectable?
What are the most common BPC-157 side effects to watch for?
Is BPC-157 legal to buy and use in 2026?
Read Next
GHK-Cu for Wound Healing and Recovery: Injectable Protocols and Surgical Repair (2026)
GHK-Cu for Skin and Hair: Topical vs Injectable Anti-Ageing Protocols (2026)
TB-500 for Achilles Tendonitis: Injection Protocol, Dosing, and Recovery Timeline (2026)
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.